While a majority of survey respondents said that they were at least somewhat familiar with current developments in oncology biosimilars, analyses of open-ended definitions found that only 1 participant could fully define a biosimilar, according to researchers.
The need for improved biosimilar education among providers has been demonstrated, and with even more anticancer biosimilars gaining FDA approval, oncologists’ education on these products is a growing area of concern.
A newly published study sought to investigate oncology providers’ understanding of biosimilars and the information and data that they feel are important to assess before prescribing these products. The researchers found that understanding of biosimilars remains low among oncologists, pharmacists, and advanced practice providers.
The investigators contacted oncology providers at a single academic healthcare system in the United States between January 2018 and May 2018. They provided an online or paper-based survey to a total of 77 providers, of whom 52 were physicians, 16 were pharmacists, and 9 were advanced practice providers.
After 50 respondents had completed the survey, the team conducted in-depth interviews that centered on themes of cost, safety and efficacy, patient preference, and disease stage.
The investigators found that, while a majority of respondents said that they were at least somewhat familiar with current developments in oncology biosimilars, analyses of open-ended definitions found that only 1 participant could fully define a biosimilar. Only 28.4% of participants correctly identified at least 1 current indication for an approved biosimilar, though 62.3% correctly identified safety and efficacy as related to interchangeability requirements.
When asked about their likelihood of using a biosimilar in practice, 53.2% said they were likely or highly likely to prescribe one. Additionally, 94.8% said they would prescribe an interchangeable product. The most important factor was a biosimilar’s safety and efficacy, followed closely by cost differences.
Colleague and expert opinion were not as highly ranked by physicians as influencing prescribing behavior, though younger or less experienced providers considered colleague and expert opinion to be more important to their choice than older providers or those who had been practicing longer.
Providers were split on the importance of informing patients about whether they were given a biosimilar; 46.8% said that informing the patient was important or extremely important, while 42.9% said it was only somewhat or not at all important. This trend aligned with viewpoints on shared decision-making; 50.6% said that shared decision-making is important or extremely important, while 39.0% said it is only somewhat or not at all important.
In total, only 10 respondents said that pharmacists should be involved in the decision-making process. Seven providers said that pharmacists should not act outside of the prescriber’s approval.
“We found, as did previous studies, that oncologists require more education regarding biosimilars before they are extensively introduced into a clinical setting,” wrote the authors, adding that “our data also suggest that there is a disconnect between what the [FDA] and academic clinicians deem most important before a biosimilar is approved and used in a clinical setting.”
Reference
Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD. Academic oncology clinicians’ understanding of biosimilar and information needed before prescribing [published online January 6, 2019]. Ther Adv Med Oncol. doi: 10.1177/1758835918818335.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.